Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GART | P22102 | 13/20 | 0.78 |
| ▸ | ATIC | P31939 | 4/20 | 0.60 |
| ▸ | FOLR2 | P14207 | 2/20 | 0.55 |
| ▸ | FOLR1 | P15328 | 2/20 | 0.55 |
| ▸ | SLC46A1 | Q96NT5 | 2/20 | 0.55 |
| ▸ | SLC19A1 | P41440 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lometrexol SCHEMBL21248426 | 0.99 | GART (0.77) | GARTATICFOLR2FOLR1SLC46A1 | |
| Lometrexol SCHEMBL21248118 | 0.96 | GART (0.73) | GARTATICFOLR2FOLR1SLC46A1 | |
| Lometrexol SCHEMBL14365 | 0.88 | GART (1.00) | GARTATIC | |
| Lometrexol SCHEMBL14469100 | 0.88 | GART (1.00) | GARTATIC | |
| Lometrexol SCHEMBL17520098 | 0.88 | GART (1.00) | GARTATIC | |
| Lometrexol SCHEMBL10067961 | 0.88 | GART (1.00) | GARTATIC | |
| Lometrexol SCHEMBL3912 | 0.87 | GART (0.60) | GARTATICFOLR2FOLR1SLC46A1 | |
| SCHEMBL20659947 | 0.85 | GART (0.62) | GARTATICFOLR2FOLR1SLC46A1 | |
| SCHEMBL1065440 | 0.85 | GART (0.62) | GARTATICFOLR2FOLR1SLC46A1 | |
| SCHEMBL6829597 | 0.85 | GART (0.62) | GARTATICFOLR2FOLR1SLC46A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11948 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130855-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2026-05-14 | — | — | US | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| EP-3706801-B1 | PLATINUM COMPLEXES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2026-01-14 | — | — | EP | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| US-20250319188-A1 | ALPHA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2025-10-16 | — | — | US | claimed |
| US-20250319123-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2025-10-16 | — | — | US | claimed |
| US-20250213577-A1 | ALPHA POLYGLUTAMATED LOMETREXOL AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2025-07-03 | — | — | US | claimed |
| US-20250195686-A1 | D GLUTAMATE POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2025-06-19 | — | — | US | claimed |
| US-20250161455-A1 | ALPHA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2025-05-22 | — | — | US | claimed |
| US-20250152511-A1 | PLATINUM COMPLEXES AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2025-05-15 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| WO-2002101391-A2 | METHOD OF USE | ELI LILLY AND COMPANY (US) | 2002-12-19 | — | — | WO | claimed |
| US-20020156023-A1 | Lometrexol combination therapy | TULARIK INC. | 2002-10-24 | — | — | US | claimed |
| WO-2002053138-A2 | TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS | SHANAHAN-PRENDERGAST ELISABETH (IE) | 2002-07-11 | — | — | WO | claimed |
| EP-1214397-A2 | METHOD FOR THE SELECTIVE PROTECTION OF PROLIFERATING NORMAL CELLS AND THE SELECTIVE ERADICATION OF TUMOR CELLS HAVING AN INACTIVE P53 PATHWAY | UNIVERSITA' DEGLI STUDI DI ROMA "LA SAPIENZA" (IT) | 2002-06-19 | — | — | EP | claimed |
| WO-2002045717-A1 | LOMETREXOL COMBINATION THERAPY | TULARIK INC. (US) | 2002-06-13 | — | — | WO | claimed |
| WO-2002043773-A2 | TISSUE SPECIFIC PRODRUGS | THE JOHNS HOPKINS UNIVERSITY (US) | 2002-06-06 | — | — | WO | claimed |
| WO-2001021765-A2 | METHOD FOR THE SELECTIVE PROTECTION OF PROLIFERATING NORMAL CELLS AND THE SELECTIVE ERADICATION OF TUMOR CELLS HAVING AN INACTIVE P53 PATHWAY | UNIVERSITA' DEGLI STUDI DI ROMA 'LA SAPIENZA' (IT) | 2001-03-29 | — | — | WO | claimed |
| EP-0505640-B1 | Improved therapeutic method | LILLY CO ELI (US) | 1995-08-23 | — | — | EP | claimed |
| US-5217974-A | Administering enzyme inhibitor as antitumor agent with folic acid or its derivatives to reduce toxicity | ELI LILLY AND COMPANY (US) | 1993-06-08 | — | — | US | claimed |